retatrutide patent eli lilly The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from still in Phase II trials. While early studies have shown promising weight-loss results, Eli Lilly's next-generation obesity treatment

The discontinuation rate in clinical trials ranged between 20% and 50% within the first year, with GI intolerance being the primary reason

If you experience heartburn or reflux-type symptoms whilst taking retatrutide (or any GLP-1-based therapy), there are several practical strategies that may help reduce discomfort

In recent years, the effects of GLP-1 agonists/analogues on the CNS have gained relevance due to emerging evidence supporting the neuroprotective effects of these molecules

By remaining consistent and collaborating closely with your healthcare provider, you can safely taper off GLP-1 medications while maintaining your progress

Not all patients are candidates for therapy, and individual results vary

2